IND Applications 101: What Sponsors Must Have in Place Before First-in-Human IND Applications 101: What Sponsors Must Have in Place Before First-in-Human In the highly regulated pharmaceutical industry, understanding the requirements for Investigational New Drug (IND) applications is crucial for sponsors aiming to commence clinical trials involving human subjects. The IND application serves as a pivotal point in a drug’s path to market, ensuring that the proposed study meets regulatory standards set by agencies such as the FDA in the United States, EMA in Europe, and MHRA in the UK. Context The IND application is an essential submission that must…

US Clinical Trial Start-Up: Regulatory Tasks on the Critical Path US Clinical Trial Start-Up: Regulatory Tasks on the Critical Path In the evolving landscape of pharmaceutical development, the initiation of clinical trials is a critical phase that demands meticulous regulatory attention. This article serves as a comprehensive manual for Regulatory Affairs (RA) professionals, specifically targeting the critical tasks involved in US clinical trial start-up and providing clarity on the regulatory frameworks governing these activities. Regulatory Context The initiation of clinical trials in the United States is primarily governed by the Food, Drug, and Cosmetic Act (FDCA) and regulations under Title…

How to Build an IND Package That Minimises Clinical Hold Risk How to Build an IND Package That Minimises Clinical Hold Risk This article serves as a comprehensive guide for Regulatory Affairs professionals involved in the preparation of Investigational New Drug (IND) applications. It details the regulations, guidelines, and strategies required to minimize clinical hold risks during the clinical trial startup phase. Regulatory Affairs Context The IND application is a critical step in the drug development process in the United States, governed primarily by the 21 CFR 312 regulations set forth by the FDA. The IND provides a mechanism for…

Pre-IND Meetings with FDA: Strategy, Timing and Briefing Book Tips Pre-IND Meetings with FDA: Strategy, Timing and Briefing Book Tips The Pre-Investigational New Drug (Pre-IND) meeting represents a pivotal opportunity for sponsors to engage with the U.S. Food and Drug Administration (FDA) early in the drug development process. This article provides a comprehensive exploration of pertinent regulations, guidelines, and best practices to optimize the Pre-IND meeting experience and ensure regulatory compliance. Context In the regulatory landscape, effective communication with the FDA is critical for successfully navigating the complexities of clinical trial regulatory approvals. By strategically utilizing Pre-IND meetings, sponsors can…

CMC Expectations in INDs: How Much Is Enough at Each Phase? CMC Expectations in INDs: How Much Is Enough at Each Phase? In the evolving landscape of pharmaceutical development, ensuring that regulatory affairs, particularly in the preparation and submission of Investigational New Drug (IND) applications, is crucial. With a focus on Chemistry, Manufacturing, and Controls (CMC), professionals must navigate various regulatory frameworks to facilitate clinical trial approvals effectively. This article provides a structured explanation of the relevant regulations, guidelines, and agency expectations in the context of IND applications within the US, UK, and EU. Regulatory Context The IND application serves…

Clinical Protocol Design Choices That Trigger IND Questions Clinical Protocol Design Choices That Trigger IND Questions Clinical trial design is a critical component in the development of new pharmaceuticals. Each decision in the protocol may have substantial regulatory implications, especially when triggering inquiries from regulatory agencies such as the FDA, EMA, and MHRA. Understanding global pharmacovigilance requirements within this context is crucial for ensuring compliance and streamlining the path toward clinical trial regulatory approvals. Context The Investigational New Drug (IND) application process is a fundamental aspect of initiating clinical trials, especially in the United States. Prior to beginning clinical investigations,…

Safety, Pharmacology and Toxicology Modules for IND Submissions Safety, Pharmacology and Toxicology Modules for IND Submissions Introduction to Regulatory Affairs in IND Submissions Within the landscape of pharmaceutical development, understanding the regulatory framework surrounding Investigational New Drug (IND) applications is crucial for successful clinical trial execution and approval. This article outlines the essential modules that pertain to safety, pharmacology, and toxicology in the context of IND submissions, detailing regulatory expectations and highlighting critical decision points for regulatory affairs (RA) professionals. Legal and Regulatory Basis The legal foundations governing IND submissions in the United States are primarily encapsulated within the Code…

Common Reasons FDA Places Studies on Clinical Hold—and How to Prevent Them Common Reasons FDA Places Studies on Clinical Hold—and How to Prevent Them Context The purpose of this article is to provide a comprehensive understanding of the reasons the U.S. Food and Drug Administration (FDA) places clinical trials under a clinical hold. This is particularly relevant for regulatory affairs (RA), chemistry, manufacturing, and controls (CMC), and labeling teams navigating the complexities of pharmaceutical laws and regulations pertaining to clinical trial regulatory approvals. Understanding these reasons and their implications is critical for ensuring the smooth progression of clinical studies and…

Coordinating IND Workstreams Across Clinical, CMC and Nonclinical Teams Coordinating IND Workstreams Across Clinical, CMC and Nonclinical Teams In the complex landscape of pharmaceutical development, ensuring regulatory compliance is paramount for the successful initiation of clinical trials. The Investigational New Drug (IND) application process plays a crucial role in this context. This article serves as a comprehensive guide for Regulatory Affairs (RA) professionals, CMC, and labelling teams in the US, UK, and EU, focusing on the intricate coordination of IND workstreams across various functional areas. Regulatory Affairs Context The IND application is a key regulatory submission in the lifecycle of…

Managing Investigator Brochure and Informed Consent from a Regulatory Lens Managing Investigator Brochure and Informed Consent from a Regulatory Lens This article aims to provide a comprehensive overview of the regulatory affairs context surrounding the Investigator Brochure (IB) and Informed Consent (IC) documentation in the realm of clinical trials. The focus will be on the frameworks established by global regulatory bodies including the FDA, EMA, and MHRA, detailing their respective guidelines and agency expectations. This practical explainer is tailored for Regulatory Affairs (RA), CMC, and Labelling teams within the pharmaceutical and biotechnology sectors, particularly those navigating clinical trial regulatory approvals…